<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427034</url>
  </required_header>
  <id_info>
    <org_study_id>A094687</org_study_id>
    <nct_id>NCT03427034</nct_id>
  </id_info>
  <brief_title>Assessment of BladderLight SurvEILlance</brief_title>
  <acronym>ABSEIL</acronym>
  <official_title>Determining the Specificity and Sensitivity of the BladderLight™ Assay as a Diagnostic and Risk Stratification Tool for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytosystems Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is BladderLight® (BL) urine testing accurate, as a non-invasive method, to exclude presence
      of bladder cancer in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are three arms to the proposed performance evaluation of the integrated test - arms 1
      and 2 are cross-sectional studies examining the accuracy of the BladderLight® test in the
      detection of cancer of the urinary bladder in patients attending either Gross Haematuria
      clinic for a potential primary (first time) diagnosis (arm 1) or patients attending
      Cystsoscopic Surveillance clinic as follow up to a previous, treated case of bladder cancer
      (arm 2). Arm 3 is a longitudinal examination of disease state following a negative cystoscopy
      with a positive BladderLight® test - this will examine whether BladderLight® can predict
      progression to overt disease. Arm three will not involve any further requirement for physical
      sampling, but will involve result checking on subsequent cystoscopies
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>all eligible patients will be recruited</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To exclude presence of bladder cancer with sensitivity of 85%</measure>
    <time_frame>12 month</time_frame>
    <description>In each cohort of the study sensitivity, specificity, negative and positive predictive value for detection of cancer will be calculated.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Cystoscopic surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haematuria group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BladderLight®</intervention_name>
    <description>Using a cell collection device to look for the presence of bladder cancer cells</description>
    <arm_group_label>Cystoscopic surveillance</arm_group_label>
    <arm_group_label>Haematuria group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 years of age or above.

          2. Patients attending Cystoscopic Surveillance clinic for monitoring of recurrence of
             urothelial carcinoma after having been treated for urothelial carcinoma / bladder
             cancer (Arm 1) OR Patients attending Gross Haematuria clinic (or equivalent) for
             cystoscopy/biopsy (if appropriate) relating to symptoms suggestive of possible
             urothelial cancer (Arm 2). Patients that will receive a cystoscopy as per standard
             practice.

          3. Able to understand and sign the written Informed Consent Form.

          4. Able and willing to follow the Protocol requirements

        Exclusion Criteria:

          1. Participation in any clinical study of an Investigational Medicinal Product during the
             8 weeks preceding the sampling period of the study.

          2. Patients that have a urinary tract stent, kidney stones or catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kasra Saeb-Parsy, MBBS, FRCSEd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kasra Paeb-Parsy, MBBS, FRCSEd</last_name>
    <phone>+44(0)7769714323</phone>
    <email>kasra.saeb-parsy@nhs.net</email>
  </overall_contact>
  <reference>
    <citation>Saeb-Parsy K, Wilson A, Scarpini C, Corcoran M, Chilcott S, McKean M, Thottakam B, Rai B, Nabi G, Rana D, Perera M, Stewart K, Laskey RA, Neal DE, Coleman N. Diagnosis of bladder cancer by immunocytochemical detection of minichromosome maintenance protein-2 in cells retrieved from urine. Br J Cancer. 2012 Oct 9;107(8):1384-91. doi: 10.1038/bjc.2012.381. Epub 2012 Sep 11.</citation>
    <PMID>22968648</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Kasra Saeb-Parsy BSc, MB BS, AFHEA, FRCSEd (Urol)</investigator_full_name>
    <investigator_title>Consultant Urologist, Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Urine</keyword>
  <keyword>Haematuria</keyword>
  <keyword>Flexible cystoscopy</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Cytology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be published in peer reviewed journals and presented at scientific meetings</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

